Vimpat® Europe In the European Union, Vimpat® (lacosamide) (film-coated tablets, syrup and solution for infusion) is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.Vimpat® is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy. USA In the US, Vimpat® (lacosamide) CV is indicatedfor the treatment of partial-onset seizures in patients 1 month of age and olderas adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.In the U.S., Vimpat® is available as oral tablets, oral solution and injection. Prescribing information Europe SmPC Vimpat® (EU). Sourced from www.ema.europa.eu. Prescribing information USA Vimpat® US Prescribing Information: tablets, oral solution and injection Other countries For availability of Vimpat® in other countries, please consult our local websites.
